O Brien Greene & Co. Inc Sells 105,006 Shares of The Joint Corp. $JYNT

O Brien Greene & Co. Inc decreased its stake in shares of The Joint Corp. (NASDAQ:JYNT) by 63.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 61,454 shares of the company’s stock after selling 105,006 shares during the quarter. O Brien Greene & Co. Inc’s holdings in Joint were worth $586,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Nisa Investment Advisors LLC lifted its stake in shares of Joint by 5,141.9% in the second quarter. Nisa Investment Advisors LLC now owns 2,254 shares of the company’s stock valued at $26,000 after buying an additional 2,211 shares during the period. Geode Capital Management LLC raised its holdings in Joint by 17.6% in the 2nd quarter. Geode Capital Management LLC now owns 345,330 shares of the company’s stock valued at $3,986,000 after acquiring an additional 51,704 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Joint by 32.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock worth $86,000 after acquiring an additional 1,810 shares during the period. Rhumbline Advisers lifted its position in shares of Joint by 25.9% in the 2nd quarter. Rhumbline Advisers now owns 20,934 shares of the company’s stock worth $242,000 after acquiring an additional 4,307 shares during the period. Finally, American Century Companies Inc. grew its holdings in shares of Joint by 13.9% during the 2nd quarter. American Century Companies Inc. now owns 27,572 shares of the company’s stock worth $318,000 after purchasing an additional 3,366 shares in the last quarter. Institutional investors and hedge funds own 76.88% of the company’s stock.

Joint Price Performance

Joint stock opened at $9.13 on Tuesday. The business has a 50 day simple moving average of $9.30 and a 200 day simple moving average of $9.26. The company has a market capitalization of $135.73 million, a PE ratio of -152.14 and a beta of 1.35. The Joint Corp. has a one year low of $7.50 and a one year high of $13.47.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. B. Riley Financial lowered Joint from a “buy” rating to a “hold” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Joint in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Joint presently has an average rating of “Hold” and an average price target of $17.00.

Insider Activity at Joint

In other news, major shareholder Charles E. Jobson bought 15,397 shares of the stock in a transaction dated Thursday, February 12th. The shares were acquired at an average price of $8.50 per share, with a total value of $130,874.50. Following the acquisition, the insider owned 1,645,294 shares in the company, valued at $13,984,999. This trade represents a 0.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have acquired 60,849 shares of company stock valued at $542,411. 27.90% of the stock is currently owned by insiders.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.